



## BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference

March 1, 2022

LAVAL, Quebec--(BUSINESS WIRE)--Mar. 1, 2022--

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42<sup>nd</sup> Annual Health Care Conference.

### Panel Details:

**Event:** Cowen & Co. 42<sup>nd</sup> Annual Health Care Conference

**Title:** Respiratory/Infections Panel

**Date/Time:** Tuesday, March 8<sup>th</sup>, 2022 at 2:10 p.m. ET

A webcast of the panel discussion may be accessed on the [Events & Presentations](#) page under the Investors & Media section of BELLUS Health's website at [www.bellushealth.com](http://www.bellushealth.com). Following the event, an archived webcast will be available on the Company's website.

### About BELLUS Health ([www.bellushealth.com](http://www.bellushealth.com))

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220301005476/en/): <https://www.businesswire.com/news/home/20220301005476/en/>

Ramzi Benamar  
Chief Financial Officer  
[rbenamar@bellushealth.com](mailto:rbenamar@bellushealth.com)

### Media:

Julia Deutsch  
Solebury Trout  
[jdeutsch@soleburytrout.com](mailto:jdeutsch@soleburytrout.com)

Source: BELLUS Health Inc.